Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

September 26, 2020

Study Completion Date

September 26, 2020

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Hyperpolarized 129-Xenon gas

Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.

DEVICE

MRI

Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.

Trial Locations (2)

27713

Duke University Medical Center, Durham

53792

University of Wisconsin Madison, Madison

All Listed Sponsors
collaborator

University of Wisconsin, Madison

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Bastiaan Driehuys

OTHER

NCT02478268 - Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter